Effects of substance P and Sar-Met-SP, a NK1 agonist, in distinct amygdaloid nuclei on anxiety-like behavior in rats

Neuroscience Letters

Volumn 569, Issue , 2014, Pages 121-125

  Bassi, Gabriel Shimizu ^a,b   De Carvalho, Milene Cristina ^a,b   Brandão, Marcus Lira ^a,b  

^a Instituto de Neuroci ncias e Comportamento   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Amygdala; Anxiety; Elevated plus maze; NK 1 receptors; Substance P

Indexed keywords

NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR AGONIST; SAR MET SP; SUBSTANCE P; UNCLASSIFIED DRUG; SUBSTANCE P, SAR(9)-MET(O2)(11)-;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; AVERSION; BASOLATERAL AMYGDALA; CENTRAL NUCLEUS (AMYGDALA); DEFENSE MECHANISM; EMOTIONALITY; INFERIOR COLLICULUS; MALE; MEDIAL AMYGDALA; MEDIOBASAL HYPOTHALAMUS; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; RAT; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; MAZE TEST; MICROINJECTION; PSYCHOLOGY; WISTAR RAT;

ANIMALS; ANXIETY; CENTRAL AMYGDALOID NUCLEUS; CORTICOMEDIAL NUCLEAR COMPLEX; MALE; MAZE LEARNING; MICROINJECTIONS; RATS, WISTAR; RECEPTORS, NEUROKININ-1; SUBSTANCE P;

EID: 84898997826     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2014.03.065     Document Type: Article

References (38)

1. Bassi G.S., Nobre M.J., de Araujo J.E., Brandao M.L. Anxiogenic effects of activation of NK-1 receptors of the dorsal periaqueductal gray as assessed by the elevated plus-maze, ultrasound vocalizations and tail-flick tests. Neuropeptides 2007, 41:365-374.
2. Blanchard D.C., Blanchard R.J. Innate and conditioned reactions to threat in rats with amygdaloid lesions. J. Comp. Physiol. Psychol. 1972, 81:281-290.
3. Boyce S., Smith D., Carlson E., Hewson L., Rigby M., O'Donnell R., Harrison T., Rupniak N.M. Intra-amygdala injection of the substance P [NK(1) receptor] antagonist L-760735 inhibits neonatal vocalisations in guinea-pigs. Neuropharmacology 2001, 41:130-137.
4. Brandao M.L., Anseloni V.Z., Pandossio J.E., De Araujo J.E., Castilho V.M. Neurochemical mechanisms of the defensive behavior in the dorsal midbrain. Neurosci. Biobehav. Rev. 1999, 23:863-875.
5. Canteras N.S., Simerly R.B., Swanson L.W. Organization of projections from the medial nucleus of the amygdala: a PHAL study in the rat. J. Comp. Neurol. 1995, 360:213-245.
6. Carvalho M.C., Santos J.M., Bassi G.S., Brandao M.L. Participation of NK1 receptors of the amygdala on the processing of different types of fear. Neurobiol. Learn. Mem. 2013, 102:20-27.
7. Cassell M.D., Wright D.J. Topography of projections from the medial prefrontal cortex to the amygdala in the rat. Brain Res. Bull. 1986, 17:321-333.
8. Dam T.V., Escher E., Quirion R. Evidence for the existence of three classes of neurokinin receptors in brain. Differential ontogeny of neurokinin-1, neurokinin-2 and neurokinin-3 binding sites in rat cerebral cortex. Brain Res. 1988, 453:372-376.
9. de Araujo J.E., Huston J.P., Brandao M.L. Aversive effects of the C-fragment of Substance P in the dorsal periaqueductal gray matter. Experimental brain research. Exp. Hirnforsch. 1998, 123:84-89.
10. De Araujo J.E., Silva R.C., Huston J.P., Brandao M.L. Anxiogenic effects of substance P and its 7-11C terminal, but not the 1-7N terminal, injected into the dorsal periaqueductal gray. Peptides 1999, 20:1437-1443.
11. Dielenberg R.A., Hunt G.E., McGregor I.S. 'When a rat smells a cat': the distribution of Fos immunoreactivity in rat brain following exposure to a predatory odor. Neuroscience 2001, 104:1085-1097.
12. Ebner K., Rupniak N.M., Saria A., Singewald N. Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:4280-4285.
13. Ebner K., Sartori S.B., Singewald N. Tachykinin receptors as therapeutic targets in stress-related disorders. Curr. Pharm. Des. 2009, 15:1647-1674.
14. Ebner K., Singewald N. The role of substance P in stress and anxiety responses. Amino Acids 2006, 31:251-272.
15. Fanselow M.S. The Midbrain Periaqueductal Gray as a Coordinator of Action in Response to Fear and Anxiety 1991, 151-173. Plenum Publishing Corp., New York.
16. Graeff F.G. Brain Defense Systems and Anxiety 1990, vol. 3:307-354. Elsevier Science Publishers, Amsterdam.
17. Gray T.S., Magnuson D.J. Peptide immunoreactive neurons in the amygdala and the bed nucleus of the stria terminalis project to the midbrain central gray in the rat. Peptides 1992, 13:451-460.
18. Gross C.T., Canteras N.S. The many paths to fear. Nat. Rev. Neurosci. 2012, 13:651-658.
19. Huston J.P., Oitzl M.S. The relationship between reinforcement and memory: parallels in the rewarding and mnemonic effects of the neuropeptide substance P. Neurosci. Biobehav. Rev. 1989, 13:171-180.
20. Kormos V., Gaszner B. Role of neuropeptides in anxiety, stress, and depression: from animals to humans. Neuropeptides 2013, 47:401-419.
21. Ledoux J.E. The amygdala: contributions to fear and stress. Sem. Neurosci. 1994, 6:231-237.
22. LeDoux J.E. The emotional brain, fear, and the amygdala. Cell. Mol. Neurobiol. 2003, 23:727-738.
23. Lew R., Geraghty D.P., Drapeau G., Regoli D., Burcher E. Binding characteristics of [125I]Bolton-Hunter [Sar9,Met(O2)11]substance P, a new selective radioligand for the NK1 receptor. Eur. J. Pharmacol. 1990, 184:97-108.
24. Nitecka L., Ben-Ari Y. Distribution of GABA-like immunoreactivity in the rat amygdaloid complex. J. Comp. Neurol. 1987, 266:45-55.
25. Nobre M.J., Brandao M.L. Analysis of freezing behavior and ultrasonic vocalization in response to foot-shocks, ultrasound signals and GABAergic inhibition in the inferior colliculus: effects of muscimol and midazolam. Eur. Neuropsychopharmacol. 2004, 14:45-52.
26. Ottersen O.P. Afferent connections to the amygdaloid complex of the rat with some observations in the cat. III. Afferents from the lower brain stem. J. Comp. Neurol. 1981, 202:335-356.
27. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 2005, 1-367. Elsevier Inc, New York.
28. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 1985, 14:149-167.
29. Regoli D., Drapeau G., Dion S., D'Orleans-Juste P. Pharmacological receptors for substance P and neurokinins. Life Sci. 1987, 40:109-117.
30. Roberts G.W., Woodhams P.L., Polak J.M., Crow T.J. Distribution of neuropeptides in the limbic system of the rat: the amygdaloid complex. Neuroscience 1982, 7:99-131.
31. Saffroy M., Beaujouan J.C., Torrens Y., Besseyre J., Bergstrom L., Glowinski J. Localization of tachykinin binding sites (NK1, NK2, NK3 ligands) in the rat brain. Peptides 1988, 9:227-241.
32. Sah P., Faber E.S., Lopez De Armentia M., Power J. The amygdaloid complex: anatomy and physiology. Physiol. Rev. 2003, 83:803-834.
33. Santos J.M., Macedo C.E., Brandao M.L. Gabaergic mechanisms of hypothalamic nuclei in the expression of conditioned fear. Neurobiol. Learn. Mem. 2008, 90:560-568.
34. Shaikh M.B., Steinberg A., Siegel A. Evidence that substance P is utilized in medial amygdaloid facilitation of defensive rage behavior in the cat. Brain Res. 1993, 625:283-294.
35. Singewald N., Chicchi G.G., Thurner C.C., Tsao K.L., Spetea M., Schmidhammer H., Sreepathi H.K., Ferraguti F., Singewald G.M., Ebner K. Modulation of basal and stress-induced amygdaloid substance P release by the potent and selective NK1 receptor antagonist L-822429. J. Neurochem. 2008, 106:2476-2488.
36. Smith D.W., Hewson L., Fuller P., Williams A.R., Wheeldon A., Rupniak N.M. The substance P antagonist L-760,735 inhibits stress-induced NK(1) receptor internalisation in the basolateral amygdala. Brain Res. 1999, 848:90-95.
37. Zanoveli J.M., Ferreira-Netto C., Brandao M.L. Conditioned place aversion organized in the dorsal periaqueductal gray recruits the laterodorsal nucleus of the thalamus and the basolateral amygdala. Exp. Neurol. 2007, 208:127-136.
38. Zhao Z., Yang Y., Walker D.L., Davis M. Effects of substance P in the amygdala, ventromedial hypothalamus, and periaqueductal gray on fear-potentiated startle. Neuropsychopharmacology 2009, 34:331-340.